Next-Generation Allosteric Integrin Modulator (Lead Candidate)
Severe tissue-destructive autoimmune disease
Pre-clinicalActive (Advancing toward clinical proof-of-concept)
Key Facts
Indication
Severe tissue-destructive autoimmune disease
Phase
Pre-clinical
Status
Active (Advancing toward clinical proof-of-concept)
Company
About AlloCyte Pharmaceuticals
AlloCyte Pharmaceuticals AG is a private, Swiss-based biotech focused on developing oral allosteric integrin modulators to protect tissue integrity by restoring natural immune balance in autoimmune diseases. The company's platform addresses the limitations of first-generation integrin therapies by avoiding paradoxical effects and broad immunosuppression. Its lead candidate is in late preclinical development, with a key milestone being clinical therapeutic proof-of-concept. The company leverages a strategic collaboration with a leading US academic clinical institution to validate its pharmacology in patient-derived materials.
View full company profile